<DOC>
	<DOCNO>NCT02573350</DOCNO>
	<brief_summary>A phase 2 , multicenter , uncontrolled , open-label trial patient MDR-TB . Only patient complete Trial 204 eligible . The trial perform globally 14 site qualify treat MDR-TB . All 434 patient complete Trial 204 eligible trial still potential clinical benefit inclusion criterion exclusion criterion meet .</brief_summary>
	<brief_title>A Phase 2 , Multi-center , Uncontrolled , Open-label Trial Evaluate Safety , Tolerability , Efficacy Orally Administered OPC-67683</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<criteria>Provide write , informed consent prior trialrelated procedure Male female patient age 18 64 year , inclusive , time enrollment 24207204 trial . Patients 64 year time 204 enrollment 65 year , eligible trial . Patients complete trial 24207204 Patients judged investigator potential clinical benefit OPC67683 exposure Able produce sputum mycobacterial culture able obtain sputum produce induction Female patient childbearing potential must negative urine pregnancy test agree use highly effective method birth control throughout participation trial 22 week last dose . Male patient must agree use adequate method contraception ( double barrier ) throughout participation trial 30weeks last dose . Greater 30 day elapse patient 's date completion 24207204 trial great 30 day elapse since patient 's trial investigator 's site initiate trial , whichever later.a A history allergy nitroimidazoles nitroimidazole derivates time . Use medication Section 5.4.7 include : use amiodarone time previous 12 month , use antiarrhythmic previous 30 day , use certain medication , include certain antidepressant , antihistamine , macrolides , previous 14 day . Any current serious concomitant condition renal impairment characterize serum creatinine level â‰¥265 mol/L hepatic impairment characterize ALT and/or aspartate transferase ( AST ) level 3 time upper limit laboratory reference range screen lab result . Current clinically relevant change ECG ( Trial 204 day 56 assessment baseline ) atrioventricular ( AV ) block , prolongation QRS complex 120 msec ( male female patient ) , QTcF interval 450 msec male patient 470 msec female patient . Current clinically relevant cardiovascular disorder heart failure , coronary artery disease , uncontrolled poorly control hypertension , arrhythmia , tachyarrhythmia status myocardial infarction . Any patient know report significant psychiatric history . For patient HIV infection , CD4 cell count le 350/mm3 treatment antiretroviral medication HIV infection . Karnofsky score 50 % hospitalize less 60 % hospitalize . Any current disease condition use nitroimidazoles nitroimidazole derivates contraindicate . Evidence clinically significant metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . Known suspected alcohol abuse , , abuse sufficient enough compromise safety cooperation patient opinion investigator . Administered IMP within 1 month prior Visit 1 OPC67683 give IMP trial 24207204 . Pregnant , breastfeeding , plan conceive father child within timeframe describe informed consent form . Recent use methadone , benzodiazepine , cocaine , amphetamine/methamphetamine , tetrahydrocannabinol , barbiturate , opiate determine urine drug screen , unless evidence provide positive drug screen result authorize medication product prescribe physician nonabuse related indication . Any disorder judgment investigator make patient good candidate trial may prevent patient reliably participate entire course trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>